- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
Entasis Therapeutics is a biotechnology business based in the US. Entasis Therapeutics shares (ETTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.19 – the same closing value as a week prior. Entasis Therapeutics employs 51 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Entasis Therapeutics stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Entasis Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ETTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Entasis Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Entasis Therapeutics stock price (NASDAQ: ETTX)
Use our graph to track the performance of ETTX stocks over time.Entasis Therapeutics shares at a glance
Latest market close | $2.19 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $2.08 |
200-day moving average | $2.17 |
Wall St. target price | $2.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.12 |
Is it a good time to buy Entasis Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Entasis Therapeutics price performance over time
Historical closes compared with the close of $2.19 from 2022-07-11
1 week (2024-10-06) | N/A |
---|---|
1 month (2024-09-13) | N/A |
3 months (2024-07-13) | N/A |
6 months (2024-04-13) | N/A |
1 year (2023-10-13) | N/A |
---|---|
2 years (2022-10-13) | N/A |
3 years (2021-10-15) | 3.15 |
5 years (2019-10-17) | 5.8 |
Entasis Therapeutics financials
Gross profit TTM | $7 million |
---|---|
Return on assets TTM | -71.67% |
Return on equity TTM | -169.78% |
Profit margin | 0% |
Book value | $0.35 |
Market Capitalization | $104.8 million |
TTM: trailing 12 months
Entasis Therapeutics share dividends
We're not expecting Entasis Therapeutics to pay a dividend over the next 12 months.
Entasis Therapeutics share price volatility
Over the last 12 months, Entasis Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entasis Therapeutics's is 1.3263. This would suggest that Entasis Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Entasis Therapeutics overview
Entasis Therapeutics Holdings Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co. , Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin.
Frequently asked questions
nullWhat percentage of Entasis Therapeutics is owned by insiders or institutions?
Currently 66.341% of Entasis Therapeutics shares are held by insiders and 10.42% by institutions. How many people work for Entasis Therapeutics?
Latest data suggests 51 work at Entasis Therapeutics. When does the fiscal year end for Entasis Therapeutics?
Entasis Therapeutics's fiscal year ends in December. Where is Entasis Therapeutics based?
Entasis Therapeutics's address is: 35 Gatehouse Drive, Waltham, MA, United States, 02451 What is Entasis Therapeutics's ISIN number?
Entasis Therapeutics's international securities identification number is: US2936141033 What is Entasis Therapeutics's CUSIP number?
Entasis Therapeutics's Committee on Uniform Securities Identification Procedures number is: 293614103
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question